82 related articles for article (PubMed ID: 21913899)
1. WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIbα receptor.
Cao C; Yang Q; Xia X; Chen Z; Liu P; Wu X; Hu H; Ding Z; Li X
Thromb Res; 2024 Jun; 238():41-51. PubMed ID: 38669962
[TBL] [Abstract][Full Text] [Related]
2. First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis.
Adili R; Tourdot BE; Mast K; Yeung J; Freedman JC; Green A; Luci DK; Jadhav A; Simeonov A; Maloney DJ; Holman TR; Holinstat M
Arterioscler Thromb Vasc Biol; 2017 Oct; 37(10):1828-1839. PubMed ID: 28775075
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis.
Zhang X; Jiang W; Richter JM; Bates JA; Reznik SK; Stachura S; Rampulla R; Doddalingappa D; Ulaganathan S; Hua J; Bostwick JS; Sum C; Posy S; Malmstrom S; Dickey J; Harden D; Lawrence RM; Guarino VR; Schumacher WA; Wong P; Yang J; Gordon DA; Wexler RR; Priestley ES
J Med Chem; 2024 Mar; 67(5):3571-3589. PubMed ID: 38385264
[TBL] [Abstract][Full Text] [Related]
4. Ultra-high throughput-based screening for the discovery of antiplatelet drugs affecting receptor dependent calcium signaling dynamics.
Fernández DI; Troitiño S; Sobota V; Tullemans BME; Zou J; van den Hurk H; García Á; Honarnejad S; Kuijpers MJE; Heemskerk JWM
Sci Rep; 2024 Mar; 14(1):6229. PubMed ID: 38486006
[TBL] [Abstract][Full Text] [Related]
5. Use of clinical biological tests of haemostasis to evaluate topical haemostatics.
Nativel F; Tollec S; Sellal KO; Trossaërt M; Grimandi G
Int J Lab Hematol; 2024 Jun; 46(3):531-537. PubMed ID: 38284282
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet and anticoagulant effects of diterpenes isolated from the marine alga, Dictyota menstrualis.
de Andrade Moura L; Marqui de Almeida AC; Domingos TF; Ortiz-Ramirez F; Cavalcanti DN; Teixeira VL; Fuly AL
Mar Drugs; 2014 Apr; 12(5):2471-84. PubMed ID: 24796305
[TBL] [Abstract][Full Text] [Related]
7. Future innovations in anti-platelet therapies.
Barrett NE; Holbrook L; Jones S; Kaiser WJ; Moraes LA; Rana R; Sage T; Stanley RG; Tucker KL; Wright B; Gibbins JM
Br J Pharmacol; 2008 Jul; 154(5):918-39. PubMed ID: 18587441
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2,3-Dihydro[1,4]dioxino[2,3-
Chen P; Chen C; Zheng Y; Chen F; Liu Z; Ren S; Song H; Liu T; Lu Z; Sun H; Kong Y; Yuan H
J Med Chem; 2024 Apr; 67(7):5502-5537. PubMed ID: 38552183
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Antiplatelet Effects of Phenol Derivatives in Humans.
Hrubša M; Alva R; Parvin MS; Macáková K; Karlíčková J; Fadraersada J; Konečný L; Moravcová M; Carazo A; Mladěnka P
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053265
[TBL] [Abstract][Full Text] [Related]
10. Protease-activated receptors in health and disease.
Peach CJ; Edgington-Mitchell LE; Bunnett NW; Schmidt BL
Physiol Rev; 2023 Jan; 103(1):717-785. PubMed ID: 35901239
[TBL] [Abstract][Full Text] [Related]
11. Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.
Lichota A; Szewczyk EM; Gwozdzinski K
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121005
[TBL] [Abstract][Full Text] [Related]
12. The domino effect triggered by the tethered ligand of the protease activated receptors.
Han X; Nieman MT
Thromb Res; 2020 Dec; 196():87-98. PubMed ID: 32853981
[TBL] [Abstract][Full Text] [Related]
13. Interspecies comparison of simultaneous thrombin and plasmin generation.
Tarandovskiy ID; Shin HKH; Baek JH; Karnaukhova E; Buehler PW
Sci Rep; 2020 Mar; 10(1):3885. PubMed ID: 32127577
[TBL] [Abstract][Full Text] [Related]
14. Novel Antiplatelet Therapies for Atherothrombotic Diseases.
Majithia A; Bhatt DL
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):546-557. PubMed ID: 30760019
[TBL] [Abstract][Full Text] [Related]
15. Human endoglin as a potential new partner involved in platelet-endothelium interactions.
Rossi E; Pericacho M; Bachelot-Loza C; Pidard D; Gaussem P; Poirault-Chassac S; Blanco FJ; Langa C; González-Manchón C; Novoa JML; Smadja DM; Bernabeu C
Cell Mol Life Sci; 2018 Apr; 75(7):1269-1284. PubMed ID: 29080903
[TBL] [Abstract][Full Text] [Related]
16. Targeting PAR1: Now What?
Flaumenhaft R; De Ceunynck K
Trends Pharmacol Sci; 2017 Aug; 38(8):701-716. PubMed ID: 28558960
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist.
Dumas M; Nadal-Wollbold F; Gaussem P; Perez M; Mirault T; Létienne R; Bourbon T; Grelac F; Le Grand B; Bachelot-Loza C
Br J Pharmacol; 2012 Mar; 165(6):1827-1835. PubMed ID: 21913899
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
Kato Y; Kita Y; Hirasawa-Taniyama Y; Nishio M; Mihara K; Ito K; Yamanaka T; Seki J; Miyata S; Mutoh S
Eur J Pharmacol; 2003 Jul; 473(2-3):163-9. PubMed ID: 12892834
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
